Cite
Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real‐world study. Authors' reply.
MLA
Hsu, Yao‐Chun, and Chun‐Ying Wu. “Editorial: Mitigating the Risk of Severe Hepatitis Flare Following Nucleoside Analogue Discontinuation—Insights from a Real‐world Study. Authors’ Reply.” Alimentary Pharmacology & Therapeutics, vol. 58, no. 5, Sept. 2023, pp. 550–51. EBSCOhost, https://doi.org/10.1111/apt.17644.
APA
Hsu, Y., & Wu, C. (2023). Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real‐world study. Authors’ reply. Alimentary Pharmacology & Therapeutics, 58(5), 550–551. https://doi.org/10.1111/apt.17644
Chicago
Hsu, Yao‐Chun, and Chun‐Ying Wu. 2023. “Editorial: Mitigating the Risk of Severe Hepatitis Flare Following Nucleoside Analogue Discontinuation—Insights from a Real‐world Study. Authors’ Reply.” Alimentary Pharmacology & Therapeutics 58 (5): 550–51. doi:10.1111/apt.17644.